SCHEMBL2234510

SCHEMBL2234510

Cc1ccc(OCCCc2ccc(C=O)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
MAPT P10636 2/20 0.64
HPGD P15428 2/20 0.64
LMNA P02545 1/20 0.64
DRD2 P14416 2/20 0.54
DRD4 P21917 2/20 0.54
DRD3 P35462 2/20 0.54
CYP2A6 P11509 1/20 0.52
KCNH2 Q12809 3/20 0.50
KDM4E B2RXH2 1/20 0.49
PPARA Q07869 2/20 0.47
PPARG P37231 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
GPR84 Q9NQS5 1/20 0.46
FFAR1 O14842 1/20 0.45
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231854 0.92 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL2232274 0.92 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL465539 0.92 HPGD (0.69) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL8390283 0.88 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL465524 0.86 HPGD (0.67) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL21185863 0.86 KCNH2 (0.62) ALDH1A1SMN1; SMN2DRD2DRD4DRD3
SCHEMBL465533 0.85 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL465467 0.85 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL21331832 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL2235851 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
EP-2528897-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS Otsuka Pharmaceutical Co., Ltd. (JP) 2012-12-05 EP disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
WO-2011093524-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 ALDH1A1 314/4885SMN1; SMN2 4081/4885MAPT 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.